334 related articles for article (PubMed ID: 20146535)
1. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
3. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.
Liu M; Kang S; Ray S; Jackson J; Zaitsev AD; Gerber SA; Cuny GD; Glicksman MA
Biochemistry; 2011 Nov; 50(43):9399-408. PubMed ID: 21961647
[TBL] [Abstract][Full Text] [Related]
4. Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors.
Liu M; Poulose S; Schuman E; Zaitsev AD; Dobson B; Auerbach K; Seyb K; Cuny GD; Glicksman MA; Stein RL; Yue Z
Anal Biochem; 2010 Sep; 404(2):186-92. PubMed ID: 20566370
[TBL] [Abstract][Full Text] [Related]
5. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.
Webber PJ; Smith AD; Sen S; Renfrow MB; Mobley JA; West AB
J Mol Biol; 2011 Sep; 412(1):94-110. PubMed ID: 21806997
[TBL] [Abstract][Full Text] [Related]
6. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
[TBL] [Abstract][Full Text] [Related]
7. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding.
Taymans JM; Vancraenenbroeck R; Ollikainen P; Beilina A; Lobbestael E; De Maeyer M; Baekelandt V; Cookson MR
PLoS One; 2011; 6(8):e23207. PubMed ID: 21858031
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 autophosphorylation enhances its GTPase activity.
Liu Z; Mobley JA; DeLucas LJ; Kahn RA; West AB
FASEB J; 2016 Jan; 30(1):336-47. PubMed ID: 26396237
[TBL] [Abstract][Full Text] [Related]
10. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
[TBL] [Abstract][Full Text] [Related]
11. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
[TBL] [Abstract][Full Text] [Related]
12. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
Tsika E; Moore DJ
Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
Xiong Y; Dawson VL; Dawson TM
Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
[TBL] [Abstract][Full Text] [Related]
14. The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.
Ray S; Bender S; Kang S; Lin R; Glicksman MA; Liu M
J Biol Chem; 2014 May; 289(19):13042-53. PubMed ID: 24695735
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
16. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR
Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
Zhang X; Kortholt A
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
[TBL] [Abstract][Full Text] [Related]
18. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
[TBL] [Abstract][Full Text] [Related]
19. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
20. The GTPase function of LRRK2.
Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1063-9. PubMed ID: 22988866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
